& Kobori, M
The STEP trials for semaglutide 2.4 mg (Wegovy) showed: Average weight loss of approximately 15% of body weight over 68 weeks One-third of participants lost 20% or more of body weight Significant reductions in waist circumference, blood pressure, and cardiovascular risk markers The SURMOUNT trials for tirzepatide (Zepbound) showed even more impressive results: Average weight loss of 20-25% at the highest dose (15 mg) over 72 weeks More than half of participants lost 20% or more of body weight Significant improvements in type 2 diabetes markers, blood pressure, and lipid profiles The head-to-head comparison is clear
Proven quality and customer-approved options are available, making it easier to find a GLP-1 patch that suits your needs
It also can help with nerve damage
Melanotan 1 Side Effect Based on the results of phase-3 clinical trials, MT-I is well tolerated with a low risk of side effects
Move your body, eat well, rest, hydrate, and go to therapy